To validate our proteomic findings and to investigate the potential of TSP4 to serve as a therapy marker, we next analyzed CSF samples derived from SMA patients before and after Nusinersen therapy by enzyme-linked immunosorbent assay (ELISA). The gene discussed is THBS4; the disease is proximal spinal muscular atrophy.